GlassScriptPhysician profile
Warren L Gray
NPI 1659379535
$910.33
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $258 · 2021: $328.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $133.35 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $122.90 | 2019-2021 | |
| Janssen Biotech, INC. | $118.53 | 2019 | |
| Abbvie INC. | $116.27 | 2019-2021 | |
| Boston Scientific Corporation | $69.67 | 2019-2021 | |
| Tolmar Pharmaceuticals, INC. | $68.33 | 2019-2021 | |
| Blue Earth Diagnostics | $55.21 | 2020-2021 | |
| Myovant Sciences INC. | $45.87 | 2021 | |
| Myriad Genetic Laboratories, INC. | $43.95 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $40.67 | 2020 | |
| Antares Pharma, INC. | $32.87 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.53 | 2019 | |
| Neotract INC. | $20.74 | 2020 | |
| Axonics, INC. | $15.44 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.